In the NewsPremier, Inc. continues growth trajectory with acquisition of Hospira’s TheraDoc
Expanding industry leading electronic clinical surveillance solutions to approximately 1,000 facilities. • Strategic combination positioned to drive quality outcomes improvement beyond current health information technology capabilities • Complementary data analytics and real-time surveillance expertise will support next-generation predictive clinical apps on an integrated technology platform • Expands Premier’s footprint by approximately 400 unaffiliated facilities • Provides opportunity to expand relationships with academic medical centers
For Immediate Release
Charlotte, N.C. (August 05, 2014)
Premier, Inc. (NASDAQ: PINC) has reached a definitive agreement to acquire TheraDoc, a market leading provider of clinical surveillance software, for $117 million in cash, subject to potential purchase price adjustments regarding TheraDoc’s actual working capital, cash and indebtedness at closing. The transaction is expected to close in Premier’s fiscal 2015 first quarter ending September 30, 2014, subject to customary closing conditions.
TheraDoc is a wholly-owned subsidiary of Hospira (NYSE: HSP). Premier’s board of directors unanimously approved… Continue reading
New article in Infection Control and Hospital Epidemiology concludes TheraDoc alerting combined with antimicrobial stewardship intervention has multiple postive effects
The following article appears in the February 2014 issue of Infection Control and Hospital Epidemiology (2014;35(2):132-138).
The article illustrates how TheraDoc’s active alerting was used in combination with antimicrobial stewardship interventions on patients with gram-negative bacteremia. The study discussed in this article was a quasi-experimental retrospective cohort study conducted at three hospitals within Detroit Medical Center, with a combined 1,100 beds. Data resulting from active alerting of a positive blood culture coupled with stewardship intervention was compiled during 2010–2011 and compared to data from patients who received no formalized stewardship intervention during 2009.
This study found that the approach taken by the antimicrobial stewardship program (ASP) at these hospitals resulted in reductions in time-to-appropriate therapy (TTAT), length-of-stay (LOS), and infection-related mortality for patients with gram-negative bacteremia who were not on appropriate empiric therapy at the time of a positive culture alert.Continue reading